MCID: CYS009
MIFTS: 42

Cystadenoma

Categories: Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Cystadenoma

MalaCards integrated aliases for Cystadenoma:

Name: Cystadenoma 11 53 43 14 71 75
Craniopharyngioma 71
Cystoma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:2634
MeSH 43 D003537
NCIt 49 C2972
SNOMED-CT 68 189680006
UMLS 71 C0010276 C0010633

Summaries for Cystadenoma

Disease Ontology: 11 An adenoma that forms a cyst.

MalaCards based summary: Cystadenoma, also known as craniopharyngioma, is related to pancreatic mucinous cystadenoma and mucinous ovarian cystadenoma, and has symptoms including visual disturbance An important gene associated with Cystadenoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Metabolism of proteins and Termination of O-glycan biosynthesis. The drugs Prednisone and Hydrocortisone succinate have been mentioned in the context of this disorder. Affiliated tissues include pancreas, appendix and ovary, and related phenotypes are Increased sensitivity to paclitaxel and homeostasis/metabolism

Wikipedia: 75 Cystadenoma (or "cystoma") is a type of cystic adenoma. When malignant, it is called... more...

Related Diseases for Cystadenoma

Diseases related to Cystadenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 889)
# Related Disease Score Top Affiliating Genes
1 pancreatic mucinous cystadenoma 32.4 PGR MUC5AC MUC1 CEACAM5 CALB2
2 mucinous ovarian cystadenoma 32.2 KRT7 KRT20 CEACAM5 AFP
3 hidrocystoma 32.2 KRT7 CEACAM5
4 pancreatic serous cystadenoma 32.2 VHL MUC6 CHGA CEACAM5
5 ovarian cystadenoma 32.1 KRT7 CEACAM5 BRCA1 AFP
6 bile duct cystadenoma 32.1 KRT7 CEACAM5
7 ovarian serous cystadenocarcinoma 31.6 SERPINA3 PTEN MUC1 GNAS CEACAM5 BRCA1
8 appendix adenocarcinoma 31.3 SYP KRT7 KRT20 GNAS CHGA CEACAM5
9 microcystic adenoma 31.1 VHL SYP MUC6 MUC1 MME CHGA
10 cystadenocarcinoma 31.1 SERPINA3 PTEN PGR MUC5AC MUC1 KRT7
11 collecting duct carcinoma 30.8 VHL MME KRT7
12 carcinoid tumors, intestinal 30.6 SYP CHGA
13 mucinous cystadenocarcinoma of pancreas 30.6 MUC6 CEACAM5
14 pancreatic cystadenocarcinoma 30.5 MUC6 CEACAM5
15 carcinoid syndrome 30.5 SYP CHGA
16 mucoepidermoid carcinoma 30.5 SERPINA3 MUC5AC MUC1 KRT7
17 intestinal obstruction 30.5 KRT7 KRT20 CEACAM5
18 islet cell tumor 30.4 SYP SERPINA3 CHGA
19 obstructive jaundice 30.3 SYP SERPINA3 KRT7 CEACAM5 AFP
20 rectal benign neoplasm 30.3 KRT7 KRT20 CEACAM5
21 pseudomyxoma peritonei 30.3 REG4 MUC6 MUC5AC MUC1 KRT7 KRT20
22 dermoid cyst of ovary 30.3 CEACAM5 AFP
23 endosalpingiosis 30.3 KRT7 CALB2 BRCA1
24 hydrocele 30.3 KRT7 CALB2 AFP
25 bile duct cystadenocarcinoma 30.3 MUC6 MUC5AC MUC1 KRT7 KRT20 CEACAM5
26 ovarian mucinous neoplasm 30.3 MUC6 MUC5AC KRT7 KRT20 CEACAM5
27 papillary adenocarcinoma 30.3 MUC1 KRT7 CEACAM5 BRCA1
28 adenoma 30.3 SYP MUC6 MUC5AC MUC1 KRT7 KRT20
29 myoma 30.3 PGR MME CEACAM5 CALB2
30 ovarian brenner tumor 30.2 KRT7 KRT20
31 goblet cell carcinoid 30.2 KRT20 CHGA
32 polycystic liver disease 1 with or without kidney cysts 30.2 MUC1 KRT7 KRT20 CEACAM5 CEACAM3 CALB2
33 hidradenoma 30.2 MUC1 MME KRT7 CEACAM5
34 syringocystadenoma papilliferum 30.2 SERPINA3 KRT7 CEACAM5
35 adenofibroma 30.2 MUC1 MME KRT7 INHA CALB2
36 adenomatoid tumor 30.2 MUC1 KRT7 CALB2 AFP
37 benign breast phyllodes tumor 30.2 PGR MME
38 bile duct cysts 30.1 KRT7 CEACAM5 AFP
39 oncocytoma 30.1 VHL SYP MUC1 MME KRT7 KRT20
40 serous cystadenocarcinoma 30.1 PTEN PGR KRT7 CALB2 BRCA1
41 renal cell carcinoma, papillary, 1 30.1 VHL PTEN MME KRT7
42 ovarian cyst 30.1 PGR MUC1 GNAS CEACAM5 BRCA1 AFP
43 cystadenofibroma 30.1 MME KRT7 CALB2 AFP
44 urethral diverticulum 30.1 KRT7 KRT20
45 adenocarcinoma 30.1 PTEN MUC5AC MUC1 KRT7 KRT20 CHGA
46 mucinous cystadenocarcinoma 30.1 SERPINA3 MUC1 KRT7 KRT20 CEACAM5 CEACAM3
47 benign mesothelioma 30.1 KRT7 KRT20 CEACAM5 CALB2
48 fibroma 30.1 SERPINA3 PGR KRT7 GNAS CALB2
49 small intestine adenocarcinoma 30.1 MUC6 MUC5AC KRT7
50 bladder urachal carcinoma 30.1 REG4 KRT7

Graphical network of the top 20 diseases related to Cystadenoma:



Diseases related to Cystadenoma

Symptoms & Phenotypes for Cystadenoma

UMLS symptoms related to Cystadenoma:


visual disturbance

GenomeRNAi Phenotypes related to Cystadenoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased sensitivity to paclitaxel GR00112-A-0 8.32 VHL

MGI Mouse Phenotypes related to Cystadenoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 AFP BRCA1 CEACAM5 CHGA GNAS INHA
2 neoplasm MP:0002006 9.97 AFP BRCA1 CEACAM5 GNAS INHA MUC1
3 normal MP:0002873 9.91 BRCA1 CALB2 GNAS INHA MUC1 PGR
4 endocrine/exocrine gland MP:0005379 9.65 AFP BRCA1 CEACAM5 CHGA GNAS INHA
5 digestive/alimentary MP:0005381 9.23 BRCA1 CEACAM5 GNAS INHA MUC1 MUC5AC

Drugs & Therapeutics for Cystadenoma

Drugs for Cystadenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
3
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
4
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
5 Antineoplastic Agents, Hormonal Phase 4
6 Hormones Phase 4
7 Hormone Antagonists Phase 4
8 glucocorticoids Phase 4
9 Anti-Inflammatory Agents Phase 4
10 Anesthetics Phase 4
11 Hydrocortisone 17-butyrate 21-propionate Phase 4
12
Ethanol Approved Phase 2, Phase 3 64-17-5 702
13
Diazoxide Approved Phase 3 364-98-7 3019
14
Exenatide Approved, Investigational Phase 3 141758-74-9 45588096
15
Glucagon Approved Phase 3 16941-32-5 16133228 16186314
16 Anti-Infective Agents, Local Phase 2, Phase 3
17 Antihypertensive Agents Phase 3
18 Vasodilator Agents Phase 3
19 Hypoglycemic Agents Phase 3
20 Glucagon-Like Peptide 1 Phase 3
21 Incretins Phase 3
22 Anti-Obesity Agents Phase 3
23
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
24
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
25
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
26
Nivolumab Approved Phase 2 946414-94-4
27
Trametinib Approved Phase 2 871700-17-3 11707110
28
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760
29
Vemurafenib Approved Phase 2 918504-65-1 42611257
30
Memantine Approved, Investigational Phase 2 41100-52-1, 19982-08-2 4054
31
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
32
Peginterferon alfa-2b Approved Phase 2 215647-85-1, 99210-65-8
33
Racemethionine Approved, Experimental, Investigational, Nutraceutical Phase 2 59-51-8, 63-68-3, 348-67-4 6137
34 Insulin, Globin Zinc Phase 2
35
Insulin Phase 2
36 Angiogenesis Inhibitors Phase 2
37 CKD732 Phase 2
38 topoisomerase I inhibitors Phase 2
39 Immune Checkpoint Inhibitors Phase 2
40 Antineoplastic Agents, Immunological Phase 2
41 Protein Kinase Inhibitors Phase 2
42 Fluorodeoxyglucose F18 Phase 2
43 Neurotransmitter Agents Phase 2
44 Dopamine Agents Phase 2
45 Antiparkinson Agents Phase 2
46 Excitatory Amino Acid Antagonists Phase 2
47 Anti-Infective Agents Phase 2
48 Antiviral Agents Phase 2
49
Pancrelipase Approved, Investigational Phase 1 53608-75-6 8519
50
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
3 EUS-Guided Pancreatic Injection of Cyst (EPIC) Trial Completed NCT00233038 Phase 2, Phase 3
4 Multicentre Double-blind Randomized Clinical Trial Assessing Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Completed NCT02860923 Phase 3 Exenatide;Placebo
5 Clinical Assessment of the Treatment With Diazoxide in Children Suffering From Obesity and Hyperinsulinemia Secondary to Surgery of Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3 DIAZOXIDE
6 Combined Diazoxide and Metformin Therapy in Children With Hypothalamic Obesity Secondary to Craniopharyngioma: A Pilot Study Completed NCT00892073 Phase 2 Diazoxide;Metformin
7 Phase II Study on the Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy Completed NCT02842723 Phase 2
8 Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension Completed NCT02063295 Phase 2 ZGN-440 sterile diluent;ZGN-440 for injectable suspension
9 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
10 Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity Completed NCT01484873 Phase 2 Exenatide
11 Intranasal Oxytocin to Promote Weight Loss in Children, Adolescents, and Adults With Brain Tumors and Hypothalamic Obesity Syndrome Completed NCT02849743 Phase 2 Syntocinon;Placebo (for Syntocinon)
12 Nivolumab and DAY101 for the Treatment of Newly Diagnosed or Recurrent Craniopharyngioma in Children and Young Adults Recruiting NCT05465174 Phase 2 Nivolumab;DAY101
13 A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection Recruiting NCT02792582 Phase 2
14 Neoadjuvant and Postoperative Treatment With Dabrafenib and Trametinib in BRAF Mutated Papillary Craniopharyngioma Recruiting NCT05525273 Phase 2 Oral dabrafenib and trametinib
15 Methionine PET/CT Studies In Patients With Cancer Recruiting NCT00840047 Phase 2 Methionine
16 Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas Recruiting NCT03224767 Phase 2 Vemurafenib;Cobimetinib
17 A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection Active, not recruiting NCT01419067 Phase 2 ^1^8F-fluorodeoxyglucose;^1^1C-methionine
18 Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study Active, not recruiting NCT03194906 Phase 2 Memantine
19 Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (Tocilizumab) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma Not yet recruiting NCT05233397 Phase 2 Tocilizumab
20 Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma Not yet recruiting NCT05286788 Phase 2 Binimetinib Oral Tablet [Mektovi]
21 Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma Terminated NCT01964300 Phase 2
22 Phase I Feasibility Trial To Study The Safety Of Sealing Resected Pancreatic Surfaces After Partial Distal Pancreatectomy Using Laser Tissue Welding Completed NCT03147768 Phase 1
23 Phase I Pilot Study of Stereotaxic Radiosurgery in Patients With Intracranial Neoplasms Completed NCT00019578 Phase 1
24 A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas Completed NCT00994500 Phase 1 vorinostat;bortezomib
25 Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
26 A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients With Recurrent or Refractory Primary CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
27 Phase I Study of Cilengitide (EMD 121974) in Children With Refractory Brain Tumors Completed NCT00063973 Phase 1 cilengitide
28 A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
29 A PHASE 1 STUDY OF ISPINESIB (SB-715992) IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS Completed NCT00363272 Phase 1 ispinesib
30 A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
31 A PHASE I STUDY OF DEPSIPEPTIDE (NSC#630176, IND# 51810) IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS AND LEUKEMIAS Completed NCT00053963 Phase 1 romidepsin
32 Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
33 EUS Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm Terminated NCT01525706 Phase 1 Ethanol and Paclitaxel Injection
34 Microenvironment: Imaging/Implications in Brain Tumors; A Preliminary Investigation of the Biodistribution of [F-18]-EF5 in Patients With Brain Tumors Terminated NCT00110032 Phase 1 EF5
35 A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
36 Diagnosis of Pancreatic Cystic Lesions With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy Unknown status NCT03884179
37 Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma Unknown status NCT00949156
38 A Phase II MULTICENTRE Trial of Needle Based Laser Confocal Endomicroscopy of Cystic and Solid Tumours of the Pancreas Completed NCT02523170
39 Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts Completed NCT01643460
40 Examining Sleep and Family Functioning in Pediatric Craniopharyngioma Using Ecological Momentary Assessment Completed NCT03330080
41 Weight Gain in Surgically Treated Adult-onset Craniopharyngioma Completed NCT01968603
42 Clinical Features and Risk Factors of Craniopharyngioma With Tumoral Hemorrhage Completed NCT04937335
43 Prospective, Multi-Center Survey Study of Children and Adolescents With Craniopharyngioma Completed NCT00258453
44 Social Participation After Childhood Craniopharyngioma Completed NCT03139526
45 Intraoperative Use of a MR Tomography System Combined With Neuronavigation - Analysis of the Craniopharyngioma Subgroup ("Intraoperative Nutzung Eines Kernspintomographie-Systems in Direkter Kopplung Mit Einem Neuronavigations-System") Completed NCT01206543
46 KRANIOPHARYNGEOM 2007 - Multicenter Prospective Study of Children and Adolescents With Craniopharyngioma Completed NCT01272622
47 Cross Sectional Study of Sleep-wake and Melatonin Patterns in Patients Treated for Craniopharyngiomas Compared to Matched Controls Completed NCT01881854
48 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens Completed NCT00919750
49 KRANIOPHARYNGEOM Registry 2019 Multicenter Registry for Patients With Childhood-onset Craniopharyngioma, Xanthogranuloma, Cysts of Rathke's Pouch, Meningioma, Pituitary Adenoma, Arachnoid Cysts Recruiting NCT04158284
50 A Phase 0/Feasibility Trial of Tocilizumab in Children and Adolescents With Newly- Diagnosed or Recurrent/Progressive Adamantinomatous Craniopharyngioma Recruiting NCT03970226 Early Phase 1 Tocilizumab

Search NIH Clinical Center for Cystadenoma

Cochrane evidence based reviews: cystadenoma

Genetic Tests for Cystadenoma

Anatomical Context for Cystadenoma

Organs/tissues related to Cystadenoma:

MalaCards : Pancreas, Appendix, Ovary, Brain, Salivary Gland, Pituitary, Spinal Cord

Publications for Cystadenoma

Articles related to Cystadenoma:

(show top 50) (show all 4129)
# Title Authors PMID Year
1
Role of cystic fluid in diagnosis of the pancreatic cystadenoma and cystadenocarcinoma. 53 62
18251127 2007
2
Expression of estrogen and progesterone receptors and inhibin-alpha in hepatobiliary cystadenoma: an immunohistochemical study. 53 62
17457606 2007
3
Epididymal cystadenomas and epithelial tumourlets: effects of VHL deficiency on the human epididymis. 53 62
16841375 2006
4
Expression of glycodelin in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastases. 53 62
16033096 2005
5
Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. 53 62
15466181 2004
6
Value of inhibin staining in gynecological pathology. 53 62
11192074 2001
7
Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. 53 62
10620446 2000
8
Expression of glycodelin in MCF-7 breast cancer cells induces differentiation into organized acinar epithelium. 53 62
9426393 1997
9
Von Hippel-Lindau syndrome. 53 62
7670659 1995
10
Laryngeal oncocytic cystadenoma and sudden death. 62
36136290 2022
11
Magnetic resonance imaging findings of cystic ovarian tumors: major differential diagnoses in five types frequently encountered in daily clinical practice. 62
35916971 2022
12
Predictors of adverse events after endoscopic ultrasound-guided through-the-needle biopsy of pancreatic cysts: a recursive partitioning analysis. 62
35451041 2022
13
Serous Cystadenoma of the Pancreas Showing Increased Uptake on 68 Ga-FAPI PET/CT. 62
35868001 2022
14
Pancreatic solid serous cystadenoma in the pancreatic head with increasing tracer uptake at 68-GaDOTA-peptide positron emission tomography: A case report. 62
36411164 2022
15
A Rare Case of Collision Tumours of the Ovary: An Ovarian Serous Cystadenoma Coexisting with Fibrothecoma. 62
36428899 2022
16
Total Laparoscopic Resection of an Extrahepatic Mucinous Biliary Cystadenoma with Liver Involvement (with Video). 62
36103012 2022
17
Mucinous cystadenoma of the ovary in a 15-year-old girl: A case report and review of the literature. 62
36270211 2022
18
Classification prediction of pancreatic cystic neoplasms based on radiomics deep learning models. 62
36447168 2022
19
[Salivary papillary cystic low-grade mucoepidermoid carcinoma and cystadenoma: a comparison of clinicopathological and genetic features]. 62
36379892 2022
20
Laparoscopy ıs a defınıtıve dıagnostıc method for auto-amputated ovary ın ınfants. 62
35964259 2022
21
MRI of Borderline Epithelial Ovarian Tumors: Pathologic Correlation and Diagnostic Challenges. 62
36083804 2022
22
Serous cystadenoma mimicking cystic pancreatic neuroendocrine tumor on 68Ga-DOTATOC PET/CT. 62
36280584 2022
23
Accuracy and agreement of a large panel of endosonographers for endomicroscopy-guided virtual biopsy of pancreatic cystic lesions. 62
36089484 2022
24
Incidental discovery of a giant ovarian cystadenoma. 62
36268316 2022
25
Biliary cystadenoma: Case report with MRI findings and surgical confirmation. 62
35991384 2022
26
Comparison of immunohistochemical characteristics of endometriomas with non-endometriotic benign ovarian cysts. 62
36314331 2022
27
An introduction to the WHO 5th edition 2022 classification of testicular tumours. 62
35502823 2022
28
[Colloid Carcinoma of the pancreas and synchronous gastrointestinal stromal tumour of stomach. A case report and review of the literature]. 62
36154734 2022
29
[Proliferative lesions with mesonephric features in the gynecologic tract: a clinicopathological analysis of sixteen cases]. 62
36207913 2022
30
A rare case of pancreatic macrocystic serous cystadenoma in an adolescent: a case report and literature review. 62
36259129 2022
31
Surgical challenges during open pancreaticoduodenectomy in a patient with situs inversus totalis: A rare case report and literature review. 62
36268427 2022
32
Delayed presentation of a huge abdominopelvic mass during the COVID-19 pandemic. 62
36117529 2022
33
A case of huge ovarian cyst in second trimester: A rare case report. 62
36268389 2022
34
Massive pancreatic serous cystadenomas raise important questions regarding surgical management of incidental pancreatic cystic lesions: a report of two cases. 62
36388676 2022
35
Analysis of CXCL8 and its receptors CXCR1/CXCR2 at the mRNA level in neoplastic tissue, as well as in serum and peritoneal fluid in patients with ovarian cance. 62
35920183 2022
36
Ovarian Cystadenomas: Growth Rate and Reliability of Imaging Measurements. 62
34846072 2022
37
Contemporary outcomes of pancreaticoduodenectomy for benign and precancerous cystic lesions. 62
35140056 2022
38
Diagnosis and Treatment of a Mixed Epithelial Stromal Tumor of the Seminal Vesicle: A Systematic Review. 62
35231450 2022
39
Oncocytic Papillary Cystadenoma of the Larynx: A Rare and Masquerading Entity. 62
36074080 2022
40
[A Case of Giant Multilocular Prostatic Cystadenoma Resected by Laparoscopic Pelvic Cystectomy : A Case Report]. 62
36199209 2022
41
Ectopic Ovarian Serous Cystadenoma Mimicking Hydrosalpinx. 62
35680031 2022
42
Microcystic serous cystadenoma mimicking pancreatic neuroendocrine neoplasm: report of a resected case with preoperative diagnostic difficulty and review of the literature. 62
36178634 2022
43
Classification of endoscopic ultrasound guided fine needle aspiration cytology of pancreatic space occupying lesions by Papanicolaou Society of Cytopathology System: A five year study. 62
36165589 2022
44
Ultrasound Findings and O-RADS Malignancy Risk Stratification of Ovarian Collision Tumors. 62
34931350 2022
45
Ectopic bronchogenic cyst of liver misdiagnosed as gallbladder diverticulum: A case report. 62
36156928 2022
46
Hepatic Cysts: Reappraisal of the Classification, Terminology, Differential Diagnosis, and Clinicopathologic Characteristics in 258 Cases. 62
35778790 2022
47
The complex and often confusing history, histology and histogenesis of mesonephric, STK11 adnexal tumour and mesonephric-like neoplasms of the upper female genital tract (including broad ligament). 62
35395118 2022
48
Revisiting the necessity for routine appendectomies in mucinous neoplasms of the ovary: An evaluation of 460 mucinous ovarian tumors. 62
35439697 2022
49
Coexistence of malignant ovarian Brenner tumor and borderline mucinous cystadenoma, combined with primary uterine corpus endometrioid carcinoma: A case report and literature review. 62
35782900 2022
50
Rare variant of type V choledochal cyst masquerading as a biliary cystadenoma. 62
35619327 2022

Variations for Cystadenoma

Expression for Cystadenoma

Search GEO for disease gene expression data for Cystadenoma.

Pathways for Cystadenoma

Pathways related to Cystadenoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.9 VHL PTEN PGR MUC6 MUC5AC MUC1
2
Show member pathways
10.97 MUC6 MUC5AC MUC1

GO Terms for Cystadenoma

Cellular components related to Cystadenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.55 SERPINA3 REG4 PTEN MUC6 MUC5AC MUC1

Sources for Cystadenoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....